Akeso's Ivonescimab Gets Green Light for Biliary Tract Cancer Treatment in China

Akeso's Latest Milestone in Cancer Treatment



Introduction


On November 16, 2026, Akeso, Inc. announced a significant advancement in cancer treatment with the acceptance of their supplemental New Drug Application (sNDA) for ivonescimab. This approval by the National Medical Products Administration (NMPA) of China is pivotal for the treatment of locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy. Previously, this application was granted Priority Review status, emphasizing its importance in clinical settings.

Understanding Ivonescimab


Ivonescimab, a monoclonal antibody, marks Akeso's fourth marketing application in China. This latest move extends its clinical development from established lung cancer treatment to gastrointestinal cancers, creating new avenues for effective therapy in a challenging area of oncology.

Study Highlights


The approval is rooted in the results from the Phase III HARMONi-GI1 study (AK112-309), a randomized, double-blind, multicenter trial assessing ivonescimab combined with standard chemotherapy against the current global treatment standard, durvalumab with chemotherapy. Notably, the HARMONi-GI1 study demonstrated:
  • - Overall Survival: The ivonescimab cohort achieved a median overall survival of 14.9 months, compared to 12.1 months for the durvalumab group, with a statistically significant p-value of 0.0031.
  • - Progression-Free Survival: The median progression-free survival was reported at 8.4 months for the ivonescimab group against 5.8 months for durvalumab (p<0.0001).
  • - Objective Response Rate: A striking 53.8% response rate was noted in the ivonescimab cohort, significantly higher than the 32.5% reported for the comparison group.

These findings were presented as a Late-Breaking Abstract during the ESMO Presidential Symposium in October 2026, highlighting the study as groundbreaking in establishing ivonescimab’s efficacy in biliary tract cancer compared to existing treatments.

Future Developments


The development journey for ivonescimab continues with the initiation of the Phase II/III study EA2251, carried out in collaboration with Summit Therapeutics and the ECOG-ACRIN Cancer Research Group. This trial aims to further investigate ivonescimab in conjunction with chemotherapy, juxtaposed against pembrolizumab or durvalumab protocols in first-line advanced BTC treatments. With this, EA2251 becomes the seventh international registrational clinical trial for ivonescimab, underscoring Akeso’s commitment to advancing cancer care.

About Akeso


Founded in 2012, Akeso has rapidly developed into a front-runner in biopharmaceutical innovation, successfully integrating a range of advanced technologies such as the Tetrabody antibody platform and AI-powered drug research. Their diverse pipeline includes over 50 innovative assets targeting vital health challenges such as cancer and autoimmune disorders, with several drugs already commercially available and more in the regulatory pipeline.

Conclusion


Akeso is forging a path towards global leadership in the biopharmaceutical sector through groundbreaking research and development, with its sights set on providing first-in-class treatments that offer improved solutions for patients facing serious health concerns. The acceptance of ivonescimab’s sNDA could mark a turning point in the management of biliary tract cancer, adding a much-needed option in a landscape of limited therapies. As Akeso continues to navigate through rigorous clinical trials and regulatory environments, the anticipation surrounding ivonescimab’s impact on cancer treatment remains high.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.